In contrast to patients with mRS 0–2, those who had mRS 3–6 showed significantly higher median plasma levels of LCN2 measured one week after stroke (75.5 vs. 43.4 ng/ml; p = 0.03; Fig 5). The gene discussed is LCN2; the disease is stroke disorder.